Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-18T17:59:47.517Z Has data issue: false hasContentIssue false
  • English
  • Français

Fasting plasma zeaxanthin response to Fructus barbarum L. (wolfberry; Kei Tze) in a food-based human supplementation trial

Published online by Cambridge University Press:  08 March 2007

Chung Yuen Cheng ,
Wai Yuen Chung ,
Yim Tong Szeto  and
Iris F. F. Benzie
Chung Yuen Cheng
Affiliation:
Antioxidant Research Group, Faculty of Health & Social Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China
Wai Yuen Chung
Affiliation:
Antioxidant Research Group, Faculty of Health & Social Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China
Yim Tong Szeto
Affiliation:
Antioxidant Research Group, Faculty of Health & Social Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China
Iris F. F. Benzie*
Affiliation:
Antioxidant Research Group, Faculty of Health & Social Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China
*
*Corresponding author: Professor Iris Benzie, fax +852 23649663, email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Age-related macular degeneration (AMD) is a common disorder that causes irreversible loss of central vision. Increased intake of foods containing zeaxanthin may be effective in preventing AMD because the macula accumulates zeaxanthin and lutein, oxygenated carotenoids with antioxidant and blue light-absorbing properties. Lycium barbarum L. is a small red berry known as Fructus lycii and wolfberry in the West, and Kei Tze and Gou Qi Zi in Asia. Wolfberry is rich in zeaxanthin dipalmitate, and is valued in Chinese culture for being good for vision. The aim of this study, which was a single-blinded, placebo-controlled, human intervention trial of parallel design, was to provide data on how fasting plasma zeaxanthin concentration changes as a result of dietary supplementation with whole wolfberries. Fasting blood was collected from healthy, consenting subjects; fourteen subjects took 15 g/d wolfberry (estimated to contain almost 3 mg zeaxanthin) for 28 d. Repeat fasting blood was collected on day 29. Age- and sex-matched controls (n 13) took no wolfberry. Responses in the two groups were compared using the Mann–Whitney test. After supplementation, plasma zeaxanthin increased 2·5-fold: mean values on day 1 and 29 were 0·038 (sem 0·003) and 0·096 (sem 0·009) μmol/l (P<0·01), respectively, for the supplementation group; and 0·038 (sem 0·003) and 0·043 (sem 0·003) μmol/l (P>0·05), respectively, for the control group. This human supplementation trial shows that zeaxanthin in whole wolfberries is bioavailable and that intake of a modest daily amount markedly increases fasting plasma zeaxanthin levels. These new data will support further study of dietary strategies to maintain macular pigment density.

Keywords

Macular pigmentAMDZeaxanthinLuteinFructus lyciiKei TzeWolfberryAntioxidantOxidative stress
Type
Research Article
Information
British Journal of Nutrition , Volume 93 , Issue 1 , January 2005 , pp. 123 - 130
Copyright
Copyright © The Nutrition Society 2005

References

Aebischer, CP, Schierle, J, Schüep, W (1999) Simultaneous determination of retinol, tocopherols, carotene, lycopene, and xanthophylls in plasma by means of reversed-phase high-performance liquid chromatography. Methods Enzymol 299, 348–362.CrossRefGoogle ScholarPubMed
Bartlett, H, Eperjesi, F (2003) Age-related macular degeneration and nutritional supplementation: a review of randomized controlled trials. Ophthal Physiol Opt 23, 383–399.CrossRefGoogle Scholar
Beatty, S, Boulton, M, Henson, D, Koh, HH, Murray, IJ (1999) Macular pigment and age related macular degeneration. Br J Ophthalmol 83, 867–877.CrossRefGoogle ScholarPubMed
Beatty, S, Koh, H, Henson, D, Boulton, M (2000) The role of oxidative stress in the pathogenesis of age-related macular. Surv Ophthalmol 45, 115–134.CrossRefGoogle ScholarPubMed
Benzie, IFF (2003) Evolution of dietary antioxidants. J Comp Biochem Physiol 136, 113–126.CrossRefGoogle ScholarPubMed
Bone, RA, Landrum, JT, Dixon, Z, Chen, Y, Llerena, CM (2000) Lutein and zeaxanthin in the eyes, serum and diet of human subjects. Exp Eye Res 71, 239–245.CrossRefGoogle ScholarPubMed
Bone, RA, Landrum, JT, Guerra, LH, Ruiz, CA (2003) Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 133, 992–998.CrossRefGoogle ScholarPubMed
Breithaupt, DE, Weller, P, Wolters, M, Hahn, A (2004) Comparison of plasma responses in human subjects after the ingestion of 3R,3R'-zeaxanthin dipalmitate from wolfberry ( Lycium barbarum ) and non-esterified 3R,3R'-zeaxanthin using chiral high-performance liquid chromatography. Br J Nutr 91, 707–713.CrossRefGoogle ScholarPubMed
Castenmiller, JJM, West, CE (1998) Bioavailability and bioconversion of carotenoids. Ann Rev Nutr 18, 19–39.CrossRefGoogle ScholarPubMed
Edge, R, McGarvey, DJ, Truscott, TG (1997) The carotenoids as anti-oxidants – a review. J Photochem Photobiol B 41, 189–200.CrossRefGoogle ScholarPubMed
Hammond, BR Jr., Johnson, EJ, Russell, RM, Krinsky, NI, Yeum, KJ, Edwards, RB, Snodderly, DM (1997) Dietary modification of human macular pigment. Invest Opthalmol Vis Sci 38, 1795–1801.Google ScholarPubMed
Hammond, BR Jr., Wooten, BR, Curran-Celentano, J (2001) Carotenoids in the retina and lens: possible acute and chronic effects on human visual performance. Arch Biochem Biophys 385, 41–46.CrossRefGoogle ScholarPubMed
Handleman, GJ, Nightingale, ZD, Lichenstein, AH, Scaefer, EJ, Blumberg, JB (1999) Lutein and zeaxanthin in plasma after dietary supplementation with egg yolk. Am J Clin Nutr 70, 247–251.CrossRefGoogle Scholar
Hartmann, D, Thurmann, PA, Spitzer, V, Schalch, W, Manner, B, Cohn, W (2004) Plasma kinetics of zeaxanthin and 3'-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. Am J Clin Nutr 79, 410–417.CrossRefGoogle Scholar
Hyman, L, Neborsky, R (2002) Risk factors for age-related macular degeneration: an update. Curr Opin Ophthalmol 13, 171–175.CrossRefGoogle ScholarPubMed
Johnson, EJ, Hammond, BR, Yeum, KJ, Qin, J, Wang, XD, Castaneda, C, Snodderly, DM, Russell, RM (2000) Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am J Clin Nutr 71, 1555–1562.CrossRefGoogle ScholarPubMed
Krinsky, NI, Landrum, JT, Bone, RA (2003) Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr 23, 171–201.CrossRefGoogle ScholarPubMed
Lam, KW, But, P (1999) The content of zeaxanthin in Gou Qi Zi, a potential health benefit to improve visual acuity. Food Chem 67, 173–176.CrossRefGoogle Scholar
Landrum, JT, Bone, RA, Joa, H, Kilburn, MD, Moore, LL, Sprague, KE (1997) A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Exp Eye Res 65, 57–62.CrossRefGoogle ScholarPubMed
Landrum, JT, Bone, RA, Moore, LL, Gomez, CM (1999) Analysis of zeaxanthin distribution within individual human retinas. Methods Enzymol 299, 457–467.CrossRefGoogle ScholarPubMed
Landrum, JT, Bone, RA (2001) Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 385, 28–40.CrossRefGoogle ScholarPubMed
Leung, IYF, Tso, MOM, Li, WWY, Lam, TT (2001) Absorption and tissue distribution of zeaxanthin and lutein in rhesus monkeys after taking Fructus lycii (Gou Qi Zi) extract. Invest Ophthalmol Vis Sci 42, 466–471.Google ScholarPubMed
Mares-Perlman, JA, Millen, AE, Ficek, TL, Hankinson, SE (2002) The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease: an overview. J Nutr 132, 518S–524S.CrossRefGoogle Scholar
Moeller, SM, Jacques, PF, Blumberg, JB (2000) The potential role of dietary xanthophylls in cataract and age-related macular degeneration. J Am Coll Nutr 19 Suppl.522S–527S.CrossRefGoogle ScholarPubMed
Mozaffarieh, M, Sacu, S, Wedrich, A (2003) The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: a review based on controversial evidence. Nutr J 2, 20–31.CrossRefGoogle ScholarPubMed
Olmedilla, B, Granado, F, Bianco, I, Vaquere, M, Cajigal, C (2001) Lutein in patients with cataracts and age-related macular degeneration: a long-term supplementation study. J Sci Food Agric 81, 904–909.CrossRefGoogle Scholar
Sommerburg, O, Keunen, JE, Bird, AC, van Kuijk, FJ (1998) Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br J Ophthalmol 82, 907–910.CrossRefGoogle ScholarPubMed
Stokkermans, TJW (2000) Treatment of age-related macular degeneration. Clin Eye Vis Care 12, 15–35.CrossRefGoogle ScholarPubMed
Verschuren, WM, Jacobs, DR, Bloemberg, BP, Kromhout, D, Menotti, A, Aravanis, C, Blackburn, H, Buzina, R, Dontas, AS, Fidanza, F (1995) Serum total cholesterol and long term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. JAMA 274, 131–136.CrossRefGoogle ScholarPubMed
Weller, P, Breithaupt, DE (2003) Identification and quatification of zeaxanthin esters in plants using liquid chromatography-mass spectrometry. J Agric Food Chem 51, 7044–7049.CrossRefGoogle Scholar
Zhou, L, Leung, I, Tso, MOM, Lam, KW (1999) The identification of dipalmityl zeaxanthin as the major carotenoid in Gou Qi Zi by high pressure liquid chromatography and mass spectrometry. J Ocul Pharmacol Ther 15, 557–565.CrossRefGoogle ScholarPubMed